Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Membrane Filtration

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   43894   clinical trials with a EudraCT protocol, of which   7300   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    19 result(s) found for: Membrane Filtration. Displaying page 1 of 1.
    EudraCT Number: 2015-003884-12 Sponsor Protocol Number: EXTRAStudy Start Date*: 2015-12-22
    Sponsor Name:AZIENDA OSPEDALIERA PAPA GIOVANNI XXIII
    Full Title: A pilot, prospective, randomized, open-label, blinded endpoint (PROBE) histopathology trial to assess the effects of ACE- inhibition therapy on glomerular proliferative lesions in patients with ext...
    Medical condition: Extracapillary glomerulonephritis
    Disease: Version SOC Term Classification Code Term Level
    20.1 10038359 - Renal and urinary disorders 10018376 Glomerulonephritis proliferative PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2011-005274-30 Sponsor Protocol Number: UCL_2011_DIDo Start Date*: 2012-08-27
    Sponsor Name:Université catholique de Louvain
    Full Title: Efficacy and safety of a Double Icodextrin Dose in elderly incident CAPD patients on incremental Peritoneal Dialysis therapy: the DIDo study
    Medical condition: Patients with chronic renal failure who are starting a Continuous Ambulatory Peritoneal Dialysis (CAPD) as first line dialyse.
    Disease: Version SOC Term Classification Code Term Level
    16.0 100000004865 10007184 CAPD LLT
    Population Age: Elderly Gender: Male, Female
    Trial protocol: BE (Completed) FR (Completed) GB (Completed)
    Trial results: (No results available)
    EudraCT Number: 2019-001619-21 Sponsor Protocol Number: OPTIMAB Start Date*: 2019-10-07
    Sponsor Name:HOSPITAL UNIVERSITARI DE BELLVITGE- IDIBELL
    Full Title: PILOT STUDY FOR THE OPTIMITZATION OF THE MAINTENANCE DOSE OF ECULIZUMAB ACCORDING TO THE WEIGHT IN ADULT PATIENTS WITH ATYPIC HEMOLYTIC UREMIC SYNDROME
    Medical condition: ATYPICAL HEMOLYTIC UREMIC SYNDROME
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004851 10079841 Atypical hemolytic uremic syndrome LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2017-005097-19 Sponsor Protocol Number: EVOLVD Start Date*: 2019-01-23
    Sponsor Name:Oslo University Hospital
    Full Title: Cholesterol lowering with EVOLocumab to prevent cardiac allograft Vasculopathy in De-novo heart transplant recipients
    Medical condition: Cardiac allograft vasculopathy in de-novo heart transplant recipients
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: NO (Ongoing) DK (Ongoing) FI (Ongoing) SE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2009-017926-38 Sponsor Protocol Number: P081226 Start Date*: 2010-08-10
    Sponsor Name:ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)
    Full Title: Traitement de la nephropathie à cylindres myelomateux. MYRE
    Medical condition: Myélome multiple compliqué d'insuffisance rénale par néphropathie à cylindre myélomateux.
    Disease: Version SOC Term Classification Code Term Level
    8.1 10029151 Traitement de la nephropathie à cylindres myelomateux PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: FR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2020-004000-33 Sponsor Protocol Number: INZ701-201 Start Date*: 2021-06-10
    Sponsor Name:Inozyme Pharma, Inc.
    Full Title: A Phase 1/2, Open-Label, Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INZ-701 Followed by an Open-Label Long-Term Extension Period i...
    Medical condition: Treatment of patients with ABCC6 Deficiency Manifesting as Pseudoxanthoma elasticum (PXE)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10010331 - Congenital, familial and genetic disorders 10037150 Pseudoxanthoma elasticum PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: FR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2016-004633-24 Sponsor Protocol Number: CRUKD/17/009 Start Date*: 2018-01-18
    Sponsor Name:Cancer Research UK
    Full Title: A Cancer Research UK Phase I/IIa trial of BT1718 (a Bicycle drug conjugate) given intravenously in patients with advanced solid tumours
    Medical condition: Advanced solid tumours refractory to conventional treatment or for which no conventional therapy exists or is declined by the patient
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004864 10065143 Malignant solid tumour LLT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2016-001042-25 Sponsor Protocol Number: ML19199 Start Date*: 2016-10-03
    Sponsor Name:F. Hoffmann-La Roche AG
    Full Title: A Study to Investigate the Impact of Pharmacogenetics on CellCept Use, in Patients Participating in a Study in Renal Transplantation
    Medical condition: Renal Transplantation
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004865 10023438 Kidney transplant LLT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: (No results available)
    EudraCT Number: 2019-004394-10 Sponsor Protocol Number: ACT16248 Start Date*: 2020-06-30
    Sponsor Name:Genzyme Corporation
    Full Title: A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Efficacy, Pharmacodynamics, and Pharmacokinetics of Lademirsen (SAR339375) for Subcutaneous Injection Administe...
    Medical condition: Congenital, hereditary and neonatal diseases
    Disease: Version SOC Term Classification Code Term Level
    20.0 10010331 - Congenital, familial and genetic disorders 10001843 Alport's syndrome PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2018-003682-34 Sponsor Protocol Number: VKTX01 Start Date*: 2019-10-23
    Sponsor Name:Vitaeris Inc.
    Full Title: A Pivotal Phase 3 Trial to Evaluate the Safety and Efficacy of Clazakizumab for the Treatment of Chronic Active Antibody-Mediated Rejection in Kidney Transplant Recipients
    Medical condition: Chronic Active Antibody-Mediated Rejection (CABMR) in Kidney Transplant Recipients
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) HU (Prematurely Ended) BE (Completed) DE (Temporarily Halted) NL (Completed) AT (Prematurely Ended) ES (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2012-004786-40 Sponsor Protocol Number: PB-102-F01 Start Date*: 2013-05-10
    Sponsor Name:Protalix Ltd.
    Full Title: A Phase 1/2, Open Label, Dose Ranging Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Exploratory Efficacy Parameters of PRX-102 Administered by Intravenous Infusion Every 2 Weeks ...
    Medical condition: Fabry disease
    Disease: Version SOC Term Classification Code Term Level
    17.0 10010331 - Congenital, familial and genetic disorders 10016016 Fabry's disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2021-006056-13 Sponsor Protocol Number: D8850C00006 Start Date*: 2022-07-26
    Sponsor Name:AstraZeneca AB
    Full Title: Open-Label, Uncontrolled, Single dose Study to Evaluate the Pharmacokinetics, Pharmacodynamics, and Safety of AZD7442 in Pediatric Participants Aged ≥ 29 weeks Gestational Age to < 18 years
    Medical condition: COVID-19
    Disease: Version SOC Term Classification Code Term Level
    23.0 10021881 - Infections and infestations 10051905 Coronavirus infection PT
    Population Age: Preterm newborn infants, Newborns, Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: DE (Completed) BE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2012-000385-38 Sponsor Protocol Number: BEL116472 Start Date*: 2012-05-18
    Sponsor Name:GlaxoSmithKline Research and Development Ltd
    Full Title: BEL116472. A 2 year mechanistic study of belimumab in Idiopathic Membranous Glomerulonephropathy
    Medical condition: Idiopathic Membranous Glomerulonephropathy (IMGN)
    Disease: Version SOC Term Classification Code Term Level
    16.1 100000004857 10027170 Membranous nephropathy LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2020-005919-51 Sponsor Protocol Number: REP0220 Start Date*: 2021-01-19
    Sponsor Name:DOMPé FARMACEUTICI S.P.A.
    Full Title: A phase 3, double-blind, randomized, placebo-controlled, multicenter study on the efficacy and safety of Reparixin in the treatment of hospitalized patients with severe COVID-19 pneumonia.
    Medical condition: COVID-19 Pneumonia
    Disease: Version SOC Term Classification Code Term Level
    20.0 10021881 - Infections and infestations 10047438 Viral infectious disorders HLGT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: View results
    EudraCT Number: 2018-000245-39 Sponsor Protocol Number: BGB-A317-303 Start Date*: 2018-06-21
    Sponsor Name:BeiGene Ltd., c/o BeiGene USA Inc.
    Full Title: A Phase 3, Open-Label, Multicenter, Randomized Study to Investigate the Efficacy and Safety of BGB-A317 (Anti−PD1 Antibody) Compared with Docetaxel in Patients with Non−Small Cell Lung Cancer Who H...
    Medical condition: Previously treated Non−Small Cell Lung Cancer in the second or third line setting.
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061873 Non-small cell lung cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SK (Ongoing) LT (Completed) BG (Ongoing) PL (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2020-001305-23 Sponsor Protocol Number: 20190505 Start Date*: 2021-09-15
    Sponsor Name:Amgen
    Full Title: A Master Protocol Evaluating the Safety and Efficacy of Therapies for Metastatic Castration-resistant Prostate Cancer (mCRPC)
    Medical condition: Metastatic Castration-resistant Prostate Cancer
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004864 10076506 Castration-resistant prostate cancer LLT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: DE (Completed) NL (Completed) SE (Completed) DK (Completed) IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2020-000828-19 Sponsor Protocol Number: NN9535-4662 Start Date*: 2021-01-25
    Sponsor Name:Novo Nordisk A/S
    Full Title: Renal mode of action of semaglutide in patients with type 2 diabetes and chronic kidney disease
    Medical condition: Diabetes Mellitus, Type 2 Chronic kidney disease
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004861 10045242 Type II diabetes mellitus LLT
    23.1 10038359 - Renal and urinary disorders 10064848 Chronic kidney disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: PL (Completed) IT (Ongoing) ES (Ongoing) DK (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2018-004207-39 Sponsor Protocol Number: AGO-OVAR2.34 Start Date*: 2021-06-07
    Sponsor Name:AGO Research GmbH
    Full Title: A randomized phase II trial of Mirvetuximab soravtansine (IMGN853), in folate receptor alpha (FRα) high recurrent ovarian cancer eligible for platinum-based chemotherapy. supported by: DIAGNOSTIC ...
    Medical condition: This trial evaluates the efficacy and safety of Mirvetuximab soravtansine (IMGN853) plus Carboplatin chemotherapy in FRα high patients with recurrent ovarian cancer who are eligible for platinum-ba...
    Disease: Version SOC Term Classification Code Term Level
    27.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10057529 Ovarian cancer metastatic PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10066697 Ovarian cancer recurrent PT
    27.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10016182 Fallopian tube cancer metastatic PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10016180 Fallopian tube cancer PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: DE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2012-003650-88 Sponsor Protocol Number: BAY94-9343/15743 Start Date*: 2015-11-25
    Sponsor Name:Bayer AG
    Full Title: A randomized, open-label, active-controlled, Phase II study of intravenous anetumab ravtansine (BAY 94-9343) or vinorelbine in patients with advanced or metastatic malignant pleural mesothelioma ov...
    Medical condition: Patients with advanced or metastatic malignant pleural mesothelioma overexpressing mesothelin
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10035605 Pleural mesothelioma malignant advanced LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FI (Completed) DE (Completed) BE (Completed) GB (Completed) ES (Completed) NL (Completed) PL (Completed) FR (Completed) IT (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Thu May 30 15:32:54 CEST 2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA